Changes in the Lung Clearance Index in Pediatric Patients With Asthma

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The multiple breath washout (MBW) is one of pulmonary function test that displays flow and gas concentration plotted against time, and shows an exponential decay in end-tidal gas concentration (washout curve). A number of of indices to describe the washout curve have been proposed, the most commonly reported is the Lung Clearance Index (LCI). This is a simple measure of ventilation heterogeneity derived from MBW, that can be used after challenge with a short action bronchodilator and in response to inhaled steroids, both in the conductive airways as acinar. Patients with moderate and severe asthma are characterized by an abnormality in both, conductive and the acinar airway. Therefore the following research question could be: what are the abnormalities in the heterogeneity of ventilation in children with mild and moderate asthma, with respect to the healthy population measured by MBW, and whether these alterations persist after challenge with inhaled steroids and B2 agonists short-acting.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital Infantil de Mexico Federico Gomez
• Treatments: Albuterol; Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Informed written consent signed by a parent or guardian of the patient and by the patient (asthma and healthy controls).

• Diagnosis of mild asthma and moderate asthma according to the criteria of the Global Initiative for Asthma 2014 (Global Strategy for Asthma Management and Prevention. National Institutes of Health 2014), treated with inhaled steroids and who come to the outpatient Clinic of Pediatric Pulmonology at Hospital Infantil de Mexico.

• An evolution of the asthma > 6 months.

• Able to perform spirometry test and multiple-breath washout test.

• No exacerbation of asthma in the past 4 weeks.

• Accept a washout period (without treatment) for 1 week before the realization of studies of pulmonary function.

• Accept the use of necessary short-acting B2 bronchodilator during the washout period.

• Do not suffer from any other chronic disease other than asthma.

Exclusion Criteria:

• Patient with acute or chronic pulmonary disease other than asthma.

• Patient with asthma exacerbation in the last 4 weeks prior to inclusion in the study.

• Patients with a diagnosis of severe asthma.

• Other co-morbidities.